KSV Pharmaceutical

KSV Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of RNA interference (RNAi) therapies. The company utilizes proprietary delivery technologies to overcome the challenges of systemic and local RNA delivery, focusing on indications with high unmet needs such as dermatology and oncology. Its lead program, KSV-001, is a siRNA therapeutic targeting TGF-beta 1 for the treatment of hypertrophic scars and keloids. Headquartered in Suzhou with R&D facilities in the United States, KSV aims to advance a diverse pipeline of nucleic acid drugs through global clinical development. The company's platform is designed to enable precise gene silencing, offering potential treatments for conditions that are difficult to address with traditional small molecules or biologics.